Welcome to our dedicated page for Provectus Biopha SEC filings (Ticker: PVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Provectus Biopharmaceuticals, Inc. (PVCT) SEC filings page on Stock Titan is intended to centralize access to the company’s U.S. regulatory disclosures as they become available, alongside AI-generated insights. Provectus describes itself as a clinical-stage biotechnology company developing immunotherapy medicines based on halogenated xanthenes, led by its rose bengal sodium platform and investigational drug PV-10. For investors and researchers, SEC documents are a key source of information on how this scientific and clinical activity is reflected in the company’s formal reporting.
While no specific filings are listed in the data provided here, typical SEC reports for a company like Provectus can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, as well as proxy statements related to annual stockholder meetings. These documents may discuss clinical trial progress, research collaborations, risk factors, financing activities, and other matters relevant to a clinical-stage biotechnology business focused on oncology, dermatology, ophthalmology, wound healing, hematology, infectious diseases, and tissue repair research.
Stock Titan’s platform enhances these filings with AI-powered summaries designed to explain complex sections in clearer language. When filings are available, users can quickly see highlights from lengthy reports, such as key updates on investigational programs like PV-10, descriptions of the rose bengal sodium-based pipeline, and discussions of corporate structure or founded entities such as VisiRose. The platform also supports real-time updates as new SEC documents are posted to the EDGAR system.
For those analyzing PVCT, this page offers a single location to review Provectus’s regulatory history as it is reported, with tools that help interpret dense disclosures and place them in the context of the company’s stated focus on halogenated xanthene-based immunotherapy medicines.
Provectus Biopharmaceuticals, Inc. (PVCT) reported an insider financing transaction by CEO and director Edward Pershing. On 11/20/2025, Pershing acquired an 8% unsecured convertible promissory note with a principal amount of
Each share of Series D-1 Preferred is convertible into 10 shares of PVCT common stock. The Series D-1 Preferred will automatically convert into common stock on
Provectus Biopharmaceuticals (PVCT) CEO and director reported acquiring an 8% unsecured convertible promissory note on 11/13/2025. The note’s outstanding principal and interest may be converted into Series D-1 Convertible Preferred Stock at $2.862 per share, and will automatically convert at that price twelve months after the issue date.
Table II lists an underlying amount of 10,483 shares of Series D-1 Preferred. Each Series D-1 Preferred share is convertible into 10 shares of common stock. The Series D-1 Preferred will automatically convert into common stock on June 26, 2026, unless converted earlier under its terms.
Provectus Biopharmaceuticals (PVCT) reported Q3 2025 results with continued operating losses and very limited liquidity. Net loss was $1.32 million for the quarter and $4.34 million for the nine months ended September 30, 2025. Cash was $72,479 as of September 30, 2025, and management stated these conditions raise substantial doubt about the company’s ability to continue as a going concern.
The company used $2.46 million in operating cash flow year‑to‑date and reported a working capital deficit of $6.19 million as of September 30, 2025. To fund operations, Provectus raised $1.525 million in unsecured 2025 convertible notes during the nine months, which bear 8% interest and automatically convert to Series D‑1 Preferred Stock after 12 months at $2.862 per share; each Series D‑1 share is convertible into 10 common shares.
The company also converted prior‑period notes into equity, issuing 869,415 Series D‑1 Preferred shares during the nine months. Common shares outstanding were 420,279,879 as of November 12, 2025. Operating expenses rose, led by general and administrative costs and stock‑based compensation, while grant revenue concluded by mid‑2025.
Provectus Biopharmaceuticals (PVCT) CEO and director Edward Pershing filed a Form 4 reporting an insider transaction on 11/06/2025. He acquired an 8% unsecured convertible promissory note issued under the company’s 2025 Financing.
The note may be converted into Series D‑1 Convertible Preferred Stock at $2.862 per share, and will automatically convert twelve months after the issue date. The filing lists 12,230 shares of Series D‑1 Preferred as the securities underlying the note. Each Series D‑1 Preferred share is convertible into 10 shares of common stock, and the preferred automatically converts to common on June 26, 2026 unless converted earlier.
Provectus Biopharmaceuticals (PVCT) CEO and Director Edward Pershing reported acquiring an 8% unsecured convertible promissory note with a principal amount of $65,000 on 10/30/2025.
The note is convertible at a price of $2.862 per share into Series D-1 Convertible Preferred Stock, representing 22,712 preferred shares. The note’s outstanding principal and interest will automatically convert into Series D-1 Preferred at $2.862 on the date that is twelve months after issuance. Each Series D-1 Preferred share converts into 10 shares of common stock and will automatically convert into common stock on June 26, 2026, unless converted earlier per its terms.
Following the reported transaction, $1,180,000 of derivative securities were beneficially owned, held directly.
Provectus Biopharmaceuticals (PVCT) CEO and director Edward Pershing reported a transaction on 10/23/2025 involving an 8% unsecured convertible promissory note. The note may be converted at a price of $2.862 per share into Series D-1 Convertible Preferred Stock.
The outstanding principal and interest of the note will automatically convert into Series D-1 Preferred twelve months after the issue date. Each share of Series D-1 Preferred is convertible into 10 shares of common stock, and the Series D-1 Preferred will automatically convert into common stock on June 26, 2026, unless converted earlier according to its terms.
Provectus Biopharmaceuticals (PVCT) CEO and director reported a non-cash conversion on 10/16/2025. An 8% unsecured convertible promissory note issued in 2024 converted into 18,880 shares of Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per preferred share. Each preferred share is convertible into 10 common shares, equating to 188,800 underlying common shares. The Series D-1 Preferred will automatically convert into common stock on June 20, 2026, unless converted earlier.
Provectus Biopharmaceuticals (PVCT) reported an insider transaction by its CEO and Director. On 10/10/2025, the reporting person acquired an 8% unsecured convertible promissory note. The note is convertible at $2.862 per share into Series D-1 Convertible Preferred Stock, with 20,965 preferred shares shown as the underlying amount. The note’s outstanding principal and interest will automatically convert into Series D-1 Preferred twelve months after its issue date. Each Series D-1 Preferred share converts into 10 common shares and will automatically convert into common stock on June 26, 2026, unless converted earlier per its terms.
Edward Pershing, CEO and director of Provectus Biopharmaceuticals, Inc. (PVCT), reported a securities transaction on 10/03/2025. He acquired an 8% unsecured convertible promissory note with a principal amount of
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals (PVCT), converted an 8% unsecured convertible promissory note issued under the company's 2024 financing into preferred and common shares. The $175,000 2024 Note converted on 09/30/2025 into 66,052 shares of Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share. Each Series D-1 share is convertible into 10 shares of common stock, producing 660,520 common shares underlying the preferred shares. The filing shows 2,484,499 shares of common stock beneficially owned following the reported transactions. The Series D-1 automatically converts into common stock on 06/20/2026 unless earlier converted under its terms.
FAQ
What is the current stock price of Provectus Biopha (PVCT)?
What is the market cap of Provectus Biopha (PVCT)?
